The New England journal of medicine
-
Editorial Comment
What Should Be the Screening Strategy for Familial Hypercholesterolemia?
-
Randomized Controlled Trial Multicenter Study
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. ⋯ In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen with romosozumab was evident at 1 year. (Funded by Amgen and UCB Pharma; FRAME ClinicalTrials.gov number, NCT01575834 .).